Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | TPH1 | P17752 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 4/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749810 | 1.00 | SIGMAR1 (0.39) | SIGMAR1JAK2TPH1ADAM17PRMT5 | |
| SCHEMBL10247590 | 0.86 | SIGMAR1 (0.39) | SIGMAR1TPH1PRMT5CHUKPDPK1 | |
| SCHEMBL17967355 | 0.82 | SIGMAR1 (0.38) | SIGMAR1JAK2TPH1PRMT5PDPK1 | |
| SCHEMBL23220225 | 0.82 | SIGMAR1 (0.41) | SIGMAR1JAK2TPH1PRMT5JAK1 | |
| SCHEMBL30945101 | 0.82 | SIGMAR1 (0.38) | SIGMAR1JAK2TPH1PRMT5PDPK1 | |
| SCHEMBL28995145 | 0.81 | SIGMAR1 (0.38) | SIGMAR1JAK2PRMT5CHUKPDPK1 | |
| SCHEMBL19059356 | 0.81 | SIGMAR1 (0.40) | SIGMAR1TPH1PRMT5CHUKSCN9A | |
| SCHEMBL24902073 | 0.81 | SIGMAR1 (0.39) | SIGMAR1JAK2TPH1PRMT5PDPK1 | |
| SCHEMBL28657112 | 0.81 | TPH1 (0.32) | TPH1 | |
| SCHEMBL19075329 | 0.79 | SIGMAR1 (0.46) | SIGMAR1TPH1PRMT5P2RX7SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873706-B2 | Process for the preparation of baricitinib and an intermediate thereof | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2018-01-23 | — | — | US | claimed |
| US-20170327507-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-16 | — | — | US | claimed |
| EP-3227298-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | Sun Pharmaceutical Industries Ltd (IN) | 2017-10-11 | — | — | EP | claimed |
| WO-2016088094-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-06-09 | — | — | WO | claimed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-3452039-B1 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | SUN PHARMACEUTICAL IND INC (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-117517528-A | Detection method of related substances in intermediate of ponatinib | 安徽迪合永欣药业有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230355629-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355629-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
| WO-2010083283-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083283-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | SIGMAR1 4082/4885JAK2 2515/4885TPH1 643/4885 |
| US-20170327507-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | JAK1, JAK3, BTK | SIGMAR1 3463/4885JAK2 5/4885TPH1 3409/4885 |
| US-20230355629-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | JAK2, JAK1, JAK3 | SIGMAR1 2339/4885JAK2 1/4885TPH1 4119/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | SIGMAR1 3743/4885JAK2 2/4885TPH1 2361/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | SIGMAR1 3460/4885JAK2 3/4885TPH1 2776/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | SIGMAR1 3460/4885JAK2 3/4885TPH1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.